Robert Hazlett
Stock Analyst at BTIG
(1.30)
# 3,544
Out of 5,182 analysts
22
Total ratings
39.13%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $8.90 | +169.66% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $84.16 | -28.71% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.88 | +1,483.89% | 2 | May 9, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $223.06 | -56.07% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $5.96 | +906.71% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $9.32 | +575.97% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $11.19 | +159.16% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.02 | +2,548,919.61% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $1.45 | +313.79% | 2 | Sep 4, 2020 | |
| KALV KalVista Pharmaceuticals | Initiates: Buy | $18 | $26.71 | -32.61% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $8.90
Upside: +169.66%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $84.16
Upside: -28.71%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.88
Upside: +1,483.89%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $223.06
Upside: -56.07%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $5.96
Upside: +906.71%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $9.32
Upside: +575.97%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $11.19
Upside: +159.16%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.02
Upside: +2,548,919.61%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.45
Upside: +313.79%
KalVista Pharmaceuticals
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $26.71
Upside: -32.61%